Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis names Covance as primary R&D partner in $2.2 billion deal

This article was originally published in Scrip

Executive Summary

In an apparent attempt to avoid the R&D job attrition that has swept other big pharma companies recently, Sanofi-Aventis is to pay Covance $1.2-2.2 billion as part of a 10-year R&D outsourcing agreement that will see hundreds of R&D employees in France and the UK transfer to the US CRO.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC010330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel